{
    "abstract": "To evaluate the safety and tolerability of encapsulated \nA single arm, open-label trial was conducted in which 1050 mg/day of encapsulated \nSeventy-five percent of participants (n = 9/12) completed the study. Seventy-five percent of study participants (n = 9/12) reported an adverse event, most of which were characterized as mild, and none were determined to be a Food and Drug Administration (FDA) serious adverse event. Most laboratory markers stayed within normal limits throughout the study period with a few clinically mild abnormalities. There was a significant decrease in pain intensity compared to baseline after the first dose (p < .01), after 4 weeks of treatment (p < .01), and after 8 weeks of treatment (p < .01). Over the 8-week intervention period, pain interference, quality of life, and sexual function and satisfaction scores improved nonsignificantly and hs-CRP decreased nonsignificantly.",
    "authors": [
        {
            "affiliation": "Helfgott Research Institute, National University of Natural Medicine, Portland, Oregon, United States.",
            "firstname": "C",
            "initials": "C",
            "lastname": "McClure"
        },
        {
            "affiliation": "Helfgott Research Institute, National University of Natural Medicine, Portland, Oregon, United States.",
            "firstname": "M",
            "initials": "M",
            "lastname": "Bollen"
        },
        {
            "affiliation": "Helfgott Research Institute, National University of Natural Medicine, Portland, Oregon, United States.",
            "firstname": "L",
            "initials": "L",
            "lastname": "Buttolph"
        },
        {
            "affiliation": "Helfgott Research Institute, National University of Natural Medicine, Portland, Oregon, United States.",
            "firstname": "E",
            "initials": "E",
            "lastname": "Stack"
        },
        {
            "affiliation": "Helfgott Research Institute, National University of Natural Medicine, Portland, Oregon, United States.",
            "firstname": "B O",
            "initials": "BO",
            "lastname": "Langley"
        },
        {
            "affiliation": "Helfgott Research Institute, National University of Natural Medicine, Portland, Oregon, United States.",
            "firstname": "D",
            "initials": "D",
            "lastname": "Hanes"
        },
        {
            "affiliation": "Oregon Health & Science University, Portland, Oregon, United States.",
            "firstname": "K M",
            "initials": "KM",
            "lastname": "Wright"
        },
        {
            "affiliation": "Helfgott Research Institute, National University of Natural Medicine, Portland, Oregon, United States.",
            "firstname": "D",
            "initials": "D",
            "lastname": "Tibbitts"
        },
        {
            "affiliation": "Helfgott Research Institute, National University of Natural Medicine, Portland, Oregon, United States.",
            "firstname": "R",
            "initials": "R",
            "lastname": "Bradley"
        }
    ],
    "conclusions": null,
    "copyrights": null,
    "doi": "10.1016/j.aimed.2022.04.003",
    "journal": "Advances in integrative medicine",
    "keywords": [
        "Botanical",
        "Dysmenorrhea",
        "Handroanthus avellanedae",
        "Handroanthus impetiginosa",
        "Menstrual cramps",
        "Pau d\u2032 arco",
        "Primary dysmenorrhea",
        "Tabebuia avellanedae",
        "Tabebuia impetiginosa",
        "Taheebo"
    ],
    "methods": null,
    "publication_date": "2023-03-25",
    "pubmed_id": "36960315\n24695505\n10465224\n20159173\n16690671\n28438280\n26841639\n19216660\n24574576\n28392498\n15829436\n18446477\n27057092\n18634864\n26779946\n27352388\n22825254\n27338330\n29317792\n2374436\n11574048\n18579323\n26451712\n18343063\n27709826\n28732760\n28577437\n27443845\n18929686\n31078660\n33182553\n12165972\n31104731\n26346418\n11690728\n32752254\n21106059\n8604867",
    "results": "Seventy-five percent of participants (n = 9/12) completed the study. Seventy-five percent of study participants (n = 9/12) reported an adverse event, most of which were characterized as mild, and none were determined to be a Food and Drug Administration (FDA) serious adverse event. Most laboratory markers stayed within normal limits throughout the study period with a few clinically mild abnormalities. There was a significant decrease in pain intensity compared to baseline after the first dose (p < .01), after 4 weeks of treatment (p < .01), and after 8 weeks of treatment (p < .01). Over the 8-week intervention period, pain interference, quality of life, and sexual function and satisfaction scores improved nonsignificantly and hs-CRP decreased nonsignificantly.",
    "title": "Safety and tolerability of Pau d' Arco (",
    "xml": "<Element 'PubmedArticle' at 0x788506f99260>"
}